SARS-CoV-2 escape


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
28 Dec 2020
Historique:
entrez: 5 1 2021
pubmed: 6 1 2021
medline: 6 1 2021
Statut: epublish

Résumé

To investigate the evolution of SARS-CoV-2 in the immune population, we co-incubated authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for 7 passages, but after 45 days, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed at day 80 by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom and South Africa of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed. Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma.

Identifiants

pubmed: 33398278
doi: 10.1101/2020.12.28.424451
pmc: PMC7781313
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI127521
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM132826
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Inflamm Regen. 2020 Aug 10;40:17
pubmed: 32834891
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Trends Immunol. 2020 Nov;41(11):1006-1022
pubmed: 33041212
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Mol Cell. 2020 Sep 3;79(5):710-727
pubmed: 32853546
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Signal Transduct Target Ther. 2020 Aug 25;5(1):170
pubmed: 32843617
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Glycobiology. 2004 Dec;14(12):1229-46
pubmed: 15175256
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Nov 19;:
pubmed: 33259788
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):270-7
pubmed: 25751231
mBio. 2019 Apr 2;10(2):
pubmed: 30940704
Retrovirology. 2013 Feb 06;10:14
pubmed: 23384254
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nature. 2020 May;581(7807):215-220
pubmed: 32225176

Auteurs

Emanuele Andreano (E)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Giulia Piccini (G)

VisMederi S.r.l, Siena, Italy.

Danilo Licastro (D)

ARGO Open Lab Platform for Genome sequencing, AREA Science Park, Padriciano, 99, 34149, Trieste, Italy.

Lorenzo Casalino (L)

Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA.

Nicole V Johnson (NV)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Ida Paciello (I)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Simeone Dal Monego (S)

ARGO Open Lab Platform for Genome sequencing, AREA Science Park, Padriciano, 99, 34149, Trieste, Italy.

Elisa Pantano (E)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Noemi Manganaro (N)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Alessandro Manenti (A)

VisMederi S.r.l, Siena, Italy.
VisMederi Research S.r.l., Siena, Italy.

Rachele Manna (R)

VisMederi S.r.l, Siena, Italy.

Elisa Casa (E)

VisMederi S.r.l, Siena, Italy.
VisMederi Research S.r.l., Siena, Italy.

Inesa Hyseni (I)

VisMederi S.r.l, Siena, Italy.
VisMederi Research S.r.l., Siena, Italy.

Linda Benincasa (L)

VisMederi Research S.r.l., Siena, Italy.

Emanuele Montomoli (E)

VisMederi S.r.l, Siena, Italy.
VisMederi Research S.r.l., Siena, Italy.
Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Rommie E Amaro (RE)

Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA.

Jason S McLellan (JS)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Rino Rappuoli (R)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Faculty of Medicine, Imperial College, London, United Kingdom.

Classifications MeSH